An Overview on Iran Medicine Market and Business Activities of Tamin Pharmaceutical Investment Company (TPICO)

Transcription

1 An Overview on Iran Medicine Market and Business Activities of Tamin Pharmaceutical Investment Company (TPICO) TPICO - Office of Strategic Studies Last Updated: Feb 2015

2 Iran, Islamic Republic at a Glance Area: 1.65 million km 2 (18 th rank) Population: million (19 th rank) Population growth (annual %): 1.3% (WB 2013) GDP (nominal): US$ billion (WB 2013, 33 rd ) GDP (PPP): US$ 1,207 billion (WB 2013, 18 th ) GDP per capita (nominal): $ 4,769 (IMF 2013, 98 th ) GDP per capita (PPP): $16,165 (IMF 2013 est., 71 st ) Exports: $61.22 billion (2013 est.) Imports: $64.42 billion (2013 est.)

3 Value of Medicines Market in Iran (bn USD) (2005 to 2014f), CAGR = +14.2% % 22% 21% 24% 23% % 22% % 25% 20% % 9% 15% 10% % % -5% % Value (bn $) Growth (%) -17% -15% -20%

4 Top 10 Manufacturing Companies in Iran 2013 (40% of locally manufactured medicines) Market Share (%) 7.00% 6.13% 6.00% 5.00% 4.77% 4.69% 4.00% 3.00% 3.99% 3.91% 3.77% 3.61% 3.40% 2.92% 2.71% 2.00% 1.00% 0.00% Companies with yellow market share % belong to TPICO

5 2.73% 2.18% 1.77% 1.69% 1.68% 16.15% Ranking of Distribution Companies % 12.48% 9.01% 7.51% 6.85% 6.32% 4.31% 1.39% 1.31% 1.13% 1.13% 1.02% 1.00% 0.88% Companies with orange market share % belong to TPICO

6 Top 10 Therapeutic Groups in Iran (50% of Iran Market) Drugs used in diabetes, 3.6% Anti-inflammatory and antirheumatic products, 3.6% Sex hormones and genital modulators, 2.7% Antiepileptics, 2.7% Antibacterials (systemic use), 14.2% Drugs for acid related disorders, 3.8% Antineoplastic agents, 6.4% Antithrombotic agents, Immunostimulants, 4.0% Blood substitutes & perfusion solutions, 4.8%

7 TAMIN PHARMACEUTICAL INVESTMENT COMPANY (TPICO)

8 TPICO Organizational Position Ministry of Cooperatives, Labor & Social Welfare Social Security Organization Social Security Investment Co. (SSIC/SHASTA) Tamin Pharmaceutical Investment Co. (TPICO)

9 Tamin Pharmaceutical Investment Company (TPICO) Established in 2003 Belongs to the Social Security Investment Company (SSIC/SHASTA) 30 Pharmaceutical companies 8,700 Workforce >800 Pharmaceutical SKUs The largest pharmaceutical holding within the country One of the largest pharmaceutical groups within the Persian Gulf & MENA Region Exports to over 50 countries on 5 continents

10 TPICO s Structure TPICO R&D API & Raw Material FP Distribution Trading - Tofigh Darou - Atra 1) Temad 2) Shimi-Darouee 3) Shirin Darou 4) Chlor Pars 5) Antibiotic Sazi 6) Atra 7) Rahavard 8) Dana 9) Farayand Gostar 10) Iran Gelatin Cap 1) Darou-Pakhsh 2) Exir 3) Farabi 4) Abou-Reyhan 5) Razak 6) Zahravi 7) Caspian Tamin 8) Pars-Darou 9) Bio-Darou 10) Shahid Ghazi 11) Zagros Pharmed 1) Darou-Pakhsh 2) Hejrat 3) Exir 4) Darou-Pakhsh veterinary 1) Gostaresh Bazargani 2) Owzan

11 Some Facts & Figures (2014) 20% Market Share of Total Market 30% Market Share of FP Manufacturers 30% Market Share of Distributors 60% Market Share of Local API Manufacturers 30% Market Share of Exported Medicines 20% Market Share of Veterinary Medicines

12 Top 5 Pharmaceutical Holdings Market Share (%) in 2013 TPICO, 19.2% Other, 48.0% Cobel, 9.4% Barekat, 8.7% HITT, 6.6% Shafa, 8.1%

13 Market Share of TPICO s Subsidiaries (2013) Pars Darou, 5% Shahid Ghazi, 5% Razak, 7% Gostaresh Bazargani Daroupakhsh, 3% Owzan(Foriathaye darouei), 0% Bio Darou, 0% Daroupakhsh-Factories, 20% Zahravi, 7% Caspian Tamin, 8% Exir, 19% Aburaihan, 10% Farabi, 15%

14 Sales Value of Pharmaceutical Holdings (2013) in billion Rial 16,000 14,000 12,000 15,963 Sales Value (bn Rial) 10,000 8,000 6,000 7,761 7,224 6,718 5,448 4,000 2,000 0 TPICO COBEL BAREKAT SHAFA HITT

15 TPICO s Companies Sales (bn USD) f CAGR = +9.1% % % 16% 17% 17% % 20% % 15% % 9% % 7% 10% 5% % -5% -10% % f -19% -20% -25%

16 Market Share of TPICO in Different Therapeutic Groups % 80% 70% 60% 50% 40% 30% 20% 10% 86% 67% 66% 61% 55% 44% 40% 39% 32% 32% 30% 28% 27% 0%

17 Top 10 Therapeutic Groups in TPICO s Basket (60% of TPICO s Basket) Anti-inflammatory and antirheumatoids, 5% Drugs used in diabetes, 6% Corticosteroids for systemic use, 4% Vitamins, 4% Agents acting on the renin-angiotensin system, 3% Blood substitutes and perfusion solutions, 7% Pituitary and hypothalamic hormones, Other, 13% 4% Sex hormones and GU modulators, 3% Antibacterials for systemic use, 24% Other nervous system drugs (Narcotics), 4%

18 TPICO s Top 10 Products 2013 Rank Product Name & Strength Basket Share (%) Market Share (%) 1 AMOXICILLIN 500MG CAP 3.77% 39% 2 METHADONE 25MG/5ML 250ML ORAL SOLUTION 2.92% 100% 3 MYCOPHENOLATE MOFETIL 500MG TAB 2.50% 93% 4 LOSARTAN POTASSIUM 25MG TAB 2.07% 75% 5 CEFIXIME 400MG TAB 1.94% 26% 6 ORLISTAT 120MG CAP 1.88% 86% 7 INSULIN ISOPHAN (NPH) HUMAN 1000U/10ML VIAL 1.87% 87% 8 CEFALEXIN 500MG CAP 1.81% 55% 9 SOMATROPIN 5MG 1.5ML PEN 1.76% 48% 10 CO-AMOXICLAV 625 (500/125) TAB 1.57% 45% 813 SKU, 22%

19 TPICO s International Partnerships

20 Cooperation, Technology Transfers & Under Licenses Manufacturing NovoNordisk: Takeda (ex. Nycomed): NovoMix Pantozol Tablet NovoRapid Pantozol Vial Norditropin 4IU Multi-Sanostol Nordilet 5IU & 10IU Multi-Sanostol + Iron Eli Lilly: Roche: Human Insulin Regular Cellcept Human Insulin NPH Roaccutane LG Life-Sciences: IVF-C IVF-M Factive

21 TPICO s Finished Medicines Export Value ( f) - Million USD F In API 10 million USD annually, including Narcotics to: Germany Netherland France Japan Malaysia Indonesia India Syria

22 Thank You For Your Attention